Literature DB >> 27226499

NCCN Evidence Blocks.

Robert W Carlson1, Eric Jonasch1.   

Abstract

NCCN has developed a series of Evidence Blocks: graphics that provide ratings for each recommended treatment regimen in terms of efficacy, toxicity, quality and consistency of the supporting data, and affordability. The NCCN Evidence Blocks are currently available in 10 tumor types within the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). At a glance, patients and providers can understand how a given treatment was assessed by the NCCN Guidelines Panel and get a sense of how a given treatment may match individual needs and preferences. Robert W. Carlson, MD, CEO of NCCN, described the reasoning behind this new feature and how the tool is used, and Eric Jonasch, MD, Professor of Genitourinary Medical Oncology at The University of Texas MD Anderson Cancer Center, and Vice Chair of the NCCN Kidney Cancer Panel, described its applicability in the management of metastatic renal cell carcinoma.
Copyright © 2016 by the National Comprehensive Cancer Network.

Entities:  

Mesh:

Year:  2016        PMID: 27226499     DOI: 10.6004/jnccn.2016.0177

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN: 1540-1405            Impact factor:   11.908


  12 in total

1.  Opportunity Costs of Receiving Palliative Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma.

Authors:  Erin M Bange; Abigail Doucette; Peter E Gabriel; Florence Porterfield; James J Harrigan; Robin Wang; Andrzej P Wojcieszynski; Ben Boursi; Bethany I Mooney; Kim A Reiss; Ronac Mamtani
Journal:  JCO Oncol Pract       Date:  2020-03-04

2.  Innovation Tops Current Trends in the 2016 Oncology Drug Pipeline.

Authors:  Dalia Buffery
Journal:  Am Health Drug Benefits       Date:  2016-06

3.  Value assessment in oncology drugs: funding of drugs for metastatic breast cancer in Canada.

Authors:  J Lemieux; S Audet
Journal:  Curr Oncol       Date:  2018-06-13       Impact factor: 3.677

4.  Measuring the Value of Pharmaceuticals in the US Health System.

Authors:  Surrey M Walton; Anirban Basu; John Mullahy; Samuel Hong; Glen T Schumock
Journal:  Pharmacoeconomics       Date:  2017-01       Impact factor: 4.981

5.  Cancer-Related Care Costs and Employment Disruption: Recommendations to Reduce Patient Economic Burden as Part of Cancer Care Delivery.

Authors:  Janet S de Moor; Courtney P Williams; Victoria S Blinder
Journal:  J Natl Cancer Inst Monogr       Date:  2022-07-05

6.  An Exploratory Analysis of the "Was It Worth It?" Questionnaire as a Novel Metric to Capture Patient Perceptions of Cancer Treatment.

Authors:  Gita Thanarajasingam; Ethan Basch; Carolyn Mead-Harvey; Antonia V Bennett; Gina L Mazza; Gisela Schwab; Jessica Roydhouse; Lauren J Rogak; Amylou C Dueck
Journal:  Value Health       Date:  2022-01-03       Impact factor: 5.101

7.  Price Transparency for Whom? In Search of Out-of-Pocket Cost Estimates to Facilitate Cost Communication in Cancer Care.

Authors:  Ya-Chen Tina Shih; Shelley Fuld Nasso; S Yousuf Zafar
Journal:  Pharmacoeconomics       Date:  2018-03       Impact factor: 4.981

8.  Biosimilar candidate IBI305 plus paclitaxel/carboplatin for the treatment of non-squamous non-small cell lung cancer.

Authors:  Yunpeng Yang; Bin Wu; Linian Huang; Meiqi Shi; Yunpeng Liu; Yanqiu Zhao; Lijun Wang; Shun Lu; Gongyan Chen; Baolan Li; Conghua Xie; Jian Fang; Nong Yang; Yiping Zhang; Jiuwei Cui; Yong Song; Cuiying Zhang; Xiaodong Mei; Bangwei Cao; Lan Yang; Ying Cheng; Kejing Ying; Tao Sun; Biyong Ren; Qitao Yu; Zijun Liao; Zhidong Pei; Mengzhao Wang; Jianying Zhou; Shiying Yu; Guosheng Feng; Huiping Wan; Huaqing Wang; Shegan Gao; Jinliang Wang; Guangyu An; Yi Geng; Yanxia Ji; Ying Yuan; Shenglin Ma; Zhongyao Jia; Mu Hu; Hui Zhou; Jie Yu; Xing Sun; Li Zhang
Journal:  Transl Lung Cancer Res       Date:  2019-12

9.  Detailed statistical assessment of the characteristics of the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) threshold rules.

Authors:  Urania Dafni; Dimitris Karlis; Xanthi Pedeli; Jan Bogaerts; George Pentheroudakis; Josep Tabernero; Christoph C Zielinski; Martine J Piccart; Elisabeth G E de Vries; Nicola Jane Latino; Jean-Yves Douillard; Nathan I Cherny
Journal:  ESMO Open       Date:  2017-10-09

10.  Potential predictive factors for pathologic complete response after the neoadjuvant treatment of rectal adenocarcinoma: a single center experience.

Authors:  Feryel Letaief; Meher Nasri; Mouna Ayadi; Khedija Meddeb; Amina Mokrani; Yosra Yahyaoui; Nesrine Chraiet; Henda Raies; Amel Mezlini
Journal:  Cancer Biol Med       Date:  2017-08       Impact factor: 4.248

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.